Latest Capital Efficiency News

GrainCorp Limited has announced an on-market buy-back of up to $50 million worth of its ordinary fully paid Class A shares, starting March 3, 2025. The move signals a strategic effort to enhance shareholder returns without specifying a fixed buy-back price or volume.

Treasury Wine Estates has announced a 20-cent per share dividend for the half-year ending December 2024, accompanied by a fully franked component and an active Dividend Reinvestment Plan.

St Barbara reveals plans to expand its 15-Mile processing plant capacity from 2.1 Mtpa to 3.0 Mtpa, integrating Cochrane Hill ore to target annual gold production exceeding 100,000 ounces.

Elixir Energy has significantly expanded its footprint in the Taroom Trough through a farmin agreement with Santos, adding substantial contingent gas resources as Eastern Australia faces an imminent gas supply shortfall.

Blue Star Helium has initiated well testing at its Great Plains assets in Lincoln County, Colorado, aiming to confirm commercial viability and guide development decisions. Positive results could accelerate the company’s expansion in North America’s helium market.

Teaminvest Private Group Limited (TIP) reported a robust 21% rise in statutory NPAT for 1H25, alongside a 1.5 cent interim dividend and ongoing share buy-back, underscoring confidence in its undervalued shares.

KGL Resources Limited has released a comprehensive feasibility study update for its Jervois Copper Project, confirming its technical robustness and financial viability with plans to commence production in 2027. The project boasts a post-tax net present value of A$405 million and aims to produce around 30,000 tonnes of copper annually, positioning itself to capitalize on a tightening global copper market.

Iron Road Ltd has announced a strategic on-market share buy-back of up to 5% of its issued capital, aiming to enhance financial flexibility for its flagship projects over the next year.

AdAlta Limited is accelerating its 'East to West' cellular immunotherapy strategy, aiming to bridge Asian innovation with Western clinical development and manufacturing to target solid cancers. The company plans to secure three assets by the end of 2025 and initiate clinical trials, positioning itself as a leader in this emerging market.

AdAlta has fast-tracked its cellular immunotherapy growth by signing two new term sheets for clinical-stage CAR-T products from Asia, pivoting to focus on in-licensing and clinical trials while winding down internal R&D on its antifibrotic drug AD-214.

Altair Minerals unveils its strategic exploration projects in Peru's prolific Venatica copper belt and Australia's Olympic Domain, aiming to unlock major copper-gold deposits with a seasoned technical team at the helm.

Nufarm Limited’s 2025 AGM revealed a resilient FY24 performance despite industry headwinds, with strong growth in omega-3 canola and strategic cost-saving initiatives setting the stage for future expansion.